AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · IEX Real-Time Price · USD
10.50
+0.31 (3.04%)
Aug 8, 2022 4:00 PM EDT - Market closed
Income Statement (Quarterly)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Quarter Ended | 2022-03-31 | 2021-12-31 | 2021-03-31 |
|---|---|---|---|
| Selling, General & Admin
|
2.05 | - | 0.4 |
| Research & Development
|
5.63 | - | 1.65 |
| Operating Expenses
|
7.68 | - | 2.05 |
| Operating Income
|
-7.68 | - | -2.05 |
| Other Expense / Income
|
-0.03 | 0 | -0 |
| Pretax Income
|
-7.66 | 0 | -2.05 |
| Net Income
|
-7.66 | - | -2.05 |
| Preferred Dividends
|
1.82 | - | 0.76 |
| Net Income Common
|
-9.48 | - | -2.81 |
| Shares Outstanding (Basic)
|
3 | 3 | 3 |
| Shares Outstanding (Diluted)
|
3 | - | 3 |
| EPS (Basic)
|
-2.98 | - | -1.07 |
| EPS (Diluted)
|
-2.98 | - | -1.07 |
| Free Cash Flow Per Share
|
-2.12 | - | -0.59 |
| EBITDA
|
-7.64 | - | -2.05 |
| Depreciation & Amortization
|
0.02 | - | 0 |
| EBIT
|
-7.66 | - | -2.05 |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).